Should you sell your Fortescue Metals Group Limited (ASX:FMG) shares?

Investors might want to consider staying away from Fortescue Metals Group Limited (ASX: FMG) shares if one mining executive’s predictions prove accurate.

According to Cleveland-Cliffs managing director Lourenco Goncalves, courtesy of the AFR, Fortescue could be the next Atlas Iron Limited (ASX: AGO).

Seven years ago today, the Atlas Iron share price was as high as $4.20. Today it is 99% lower at just 4.2 cents.

Why is Fortescue being tipped as the next Atlas Iron?

During a discussion about price discounts which are being applied to lower grade iron ore, Mr Goncalves suggested that changing dynamics in the iron ore market could lead Fortescue Metals into financial distress.

While I’m not as bearish on Fortescue as Mr Goncalves is, I do agree that the preference for higher grade ore and the widening discount it is experiencing is a major concern.

Why is high grade ore preferred?

The biggest consumer of iron ore is of course Chinese steel makers. Unfortunately, for low grade producers like Fortescue Metals, these steel makers are buying higher grade ore right now.

Higher grade products, which produce more steel for each tonne that is used and can also reduce emissions, have been growing in demand on the back of potential production cuts and pollution concerns.

Chinese regulators are aiming to reduce smog by forcing heavy industry in cities around Beijing to slash production during the winter heating season.

Should you sell your Fortescue shares?

As things stand now, I would be a seller of Fortescue Metals’ shares and a buyer of more diversified and higher grade producers such as BHP Billiton Limited (ASX: BHP) and Rio Tinto Limited (ASX: RIO).

However, it could be worth holding on for a few more days as Fortescue Metals is expected to update the market on its pricing and exports on Thursday of this week. But if there’s no improvement, I would move on in a hurry.

Instead of iron ore miners, this small cap healthcare share could be a great option for investors.

The ASX small cap up 285% with no sign of stopping...

One Australian company has developed a state of the art device that's revolutionizing hospitals all over the world. Even better, this device is so profitable that the company rakes in 90% margins. That's a lot of cash. So no wonder the stock's up 285% since 2008 – with no signs of stopping...

To discover the name and code, simply click the link below. You'll discover our expert's #1 medical technology pick... and you can decide for yourself whether to get invested today.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.